<DOC>
	<DOCNO>NCT01283399</DOCNO>
	<brief_summary>This observational study ass efficacy safety combination rituximab ( MabThera ) methotrexate participant active refractory rheumatoid arthritis ( RA ) fail respond single course anti-tumor necrosis factor ( TNF ) therapy routine clinical practice . Data collect participant 12 month first dose rituximab minimum 6 month follow rituximab re-treatment course .</brief_summary>
	<brief_title>An Observational Study Rituximab Combination With Methotrexate Participants With Active Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>Active rheumatoid arthritis Inadequate response single TNF inhibitor Participants receive rituximab therapy accordance prescribe information Signed data release form within 6 week ( 42 day ) initiate rituximab therapy Women childbearing potential must use effective form contraception Contraindication receive rituximab accord local label Previous treatment rituximab Treatment investigational drug within 30 day prior enrolment</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>